BerGenBio updates merger, rights issue timeline

BerGenBio ASA has updated the timelines for its planned statutory triangular merger with Oncoinvent ASA and BerGenBio Norge AS, and a fully underwritten rights issue. The changes are due to delays in preparing the EEA prospectus for the offering and listing of new shares.

The first draft of the prospectus has been submitted to the Norwegian Financial Supervisory Authority and is expected to be approved around October 28, 2025. The merger is then anticipated to complete on or about October 29, 2025, with combined company shares beginning trading on Euronext Oslo Børs around October 30, 2025.

The subscription period for the rights issue is now expected to start on November 14, 2025, at 09:00 CET and conclude on November 28, 2025, at 16:30 CET. Delivery of the new shares is projected for approximately December 8, 2025.